在治疗晚期乳腺癌方面Capivasertib的成本效益:美国的医疗保健前景
Chijioke Okeke1,2, Javeria Khalid2, J Douglas Thornton1,2
1The Prescription Drug Misuse Education and Research Center, College of Pharmacy, University of Houston, TX.
Journal of managed care & specialty pharmacy
|August 30, 2025
概括
根据目前的价格,将capivasertib添加到复发乳腺癌中是不具有成本效益的. 需要进一步的价格谈判以与美国医疗保健系统保持一致
科学领域:
- 癌症学
- 健康经济学
- 药物经济学
背景情况:
- 与荷尔蒙疗法 (fulvestrant) 结合的capivasertib已被批准用于HR+/ HER2-高级乳腺癌.
- 在CapiTello-291试验中,capivasertib与fulvestrant的疗效优于单独的fulvestrant.
研究的目的:
- 在美国评估capivasertib与fulvestrant单一治疗对HR+/ HER2-高级乳腺癌的成本效益.
- 从付款人的角度评估经济价值.
主要方法:
- 使用了708名参与者和3个健康状态 (无进展,进展性疾病,死亡) 的马尔科夫模型.
- 来自CapiTello-291试验的数据为模型提供了信息,使用100,000美元/QALY的支付意愿门.
- 进行了敏感性分析以评估模型的不确定性.
主要成果:
- 基本模型显示,获得0.62 QALY的增量成本为79,117.66美元,产生128,283.61美元/QALY的ICER.
- 在13万美元/QALY时,Capivasertib加上Fulvestrant的成本效益概率为50%,在500,100美元/QALY时则为100%.
结论:
- 在目前的价格下,在美国医疗保健系统中,将capivasertib添加到fulvestrant是不具有成本效益的.
- 关于capivasertib价格的谈判对于提高其成本效益和融入标准治疗至关重要.
更多相关视频
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.5K
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
11.0K
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Cancer Survival Analysis
448
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448
Kaplan-Meier Approach
258
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
258
